-transparent.png){kind=logo}
Enhancement of growth of a B10.D2 fibrosarcoma in B6AF1 recipients could be induced by administration of B6AF1 anti-B10.D2 lymphocyte serum. The role of the Fc part in this phenomenon was studied by treatment of the B6AF1 recipients with F(ab')2 fragments of enhancing alloantibodies. A highly purified F(ab')2 preparation was used to exclude any effects of undigested IgG. Administration of F(ab')2 did not lead to enhancement of the tumor allografts, not even when given in a dose that was 22 times the molar amount of the lowest enhancing dose of undigested IgG. We therefore conclude that passive enhancement of mouse tumor allografts by alloantibodies is Fc dependent.
Related Publications
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
February 1979,
Journal of immunology (Baltimore, Md. : 1950),
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
March 1979,
Transplantation proceedings,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
November 1981,
Transplantation,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
November 1976,
Transplantation,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
June 1982,
Transplantation proceedings,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
August 1974,
Transplantation,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
March 1976,
Transplantation,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
February 1971,
Transplantation,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
June 1972,
Transplantation,
R M de Waal, and
I M Cornelissen, and
P J Capel, and
R A Koene
November 1974,
Transplantation,
